Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. VBI Vaccines's Total Liabilities for the quarter that ended in Dec. 2023 was $79.42 Mil. VBI Vaccines's Total Assets for the quarter that ended in Dec. 2023 was $86.95 Mil.
Therefore, VBI Vaccines's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.91.
VBI Vaccines Liabilities-to-Assets Historical Data
The historical data trend for VBI Vaccines's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of VBI Vaccines's Liabilities-to-Assets
For the Biotechnology subindustry, VBI Vaccines's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VBI Vaccines's Liabilities-to-Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VBI Vaccines's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where VBI Vaccines's Liabilities-to-Assets falls into.
VBI Vaccines Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
VBI Vaccines's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
VBI Vaccines Liabilities-to-Assets Related Terms
Thank you for viewing the detailed overview of VBI Vaccines's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VBIV has been successfully added to your 